The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Open accessAbstract
BACKGROUND: Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 diabetes is unknown. METHODS: In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg) subcutaneously once weekly for 72 weeks. The primary end point was the percent change in weight from baseline to week 72. Key secondary end points included weight reductions of at least 10%, 15%, 20%, and 25% and a change in waist circumference from baseline to week 72. RESULTS: A total of 751 participants underwent randomization. The least-squares mean percent change in weight at week 72 was -20.2% (95% confidence interval [CI], -21.4 to -19.1) with tirzepatide and -13.7% (95% CI, -14.9 to -12.6) with semaglutide (P<0.001). The least-squares mean change in waist circumference was -18.4 cm (95% CI, -19.6 to -17.2) with tirzepatide and -13.0 cm (95% CI, -14.3 to -11.7) with semaglutide (P<0.001). Participants in the tirzepatide group were more likely than those in the semaglutide group to have weight reductions of at least 10%, 15%, 20%, and 25%. The most common adverse events in both treatment groups were gastrointestinal, and most were mild to moderate in severity and occurred primarily during dose escalation. CONCLUSIONS: Among participants with obesity but without diabetes, treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight and waist circumference at week 72. (Funded by Eli Lilly; SURMOUNT-5 ClinicalTrials.gov number, NCT05822830.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tirzepatide also leads to greater weight loss than semaglutide for people with type 2 diabetes 14 and than liraglutide for people with obesity.15”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [15]
In the citing paper
“In the STEP-8 trial, 70 semaglutide 2•4 mg/week led to greater weight loss (a 15•8% reduction) compared with liraglutide 3•0 mg once daily (a 6•4% reduction); in the SURMOUNT-5 trial, 15 tirzepatide 15 mg caused significantly higher weight reduction (20•2%) compared with semaglutide 2•4 mg (13•7%”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [15]
In the citing paper
“in the SURMOUNT-5 trial, 15 tirzepatide 15 mg caused significantly higher weight reduction (20•2%) compared with semaglutide 2•4 mg (13•7% )”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [15]
In the citing paper
“Similar differences in effectiveness are found when looking at reductions in waist circumference, systolic blood pressure, and serum triglycerides, with differences in effect sizes reflecting the differences in weight loss in response to liraglutide, semaglutide, and tirzepatide treatment.15,70”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [15]
In the citing paper
“The efficacy of GLP-1 receptor agonists (GLP-1 RAs) in older adults has been robustly demonstrated in randomized controlled trials (RCTs) [34], providing strong evidence for their use in managing obesity and related comorbidities in individuals aged over 65.”
From A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass (2026) · cites this paper as [34]
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,472
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Whelton, P. K. (2002) · JAMA · doi:10.1001/jama.288.15.1882 · Cited by 1,473
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404881 · Cited by 871
Self-citationTwo-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868
Cited by
Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes
Nicholls, S. J., Pavo, I., Bhatt, D. L., Buse, J. B., Del Prato, S., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Miller, D., Nauck, M. A., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2505928 · Cited by 223
Celletti, F., Farrar, J., & De Regil, L. (2026) · JAMA · doi:10.1001/jama.2025.24288 · Cited by 153
Wharton, S., Freitas, P., Hjelmesæth, J., Kabisch, M., Kandler, K., Lingvay, I., Quiroga, M., Rosenstock, J., & Garvey, W. T. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00226-8 · Cited by 119
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Dahl, K., Toubro, S., Dey, S., Duque do Vale, R., Flint, A., Gasiorek, A., Heydorn, A., Jastreboff, A. M., Key, C., Petersen, S. B., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01185-7 · Cited by 80
Metadata
- Authors
- Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., & Dunn, J. P.
- Affiliations
- Weill Cornell Medicine (US)
- University of Texas Center for Obesity Medicine and Metabolic Performance, Department of Surgery, University of Texas McGovern Medical School, Houston
- Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin
- University of California, Los Angeles (US)
- Eli Lilly, Indianapolis
- Eli Lilly (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-07-03
- Volume
- 393
- Issue
- 1
- Pages
- 26-36
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4410277932
- Cited by
- 634
- References
- 40
- Citations by year
- 2026: 448 · 2025: 186
- FWCI
- 355.83
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- eCommons (Cornell University) (submittedVersion, cc-by-nc-nd)
- Funders
- Eli Lilly and Company (NA)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- tirzepatide, semaglutide, obesity, weight loss, waist circumference, GLP-1 receptor agonists, GIP/GLP-1 receptor agonist, gastrointestinal adverse effects, non-diabetic obesity
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Adult, Aged, Body Weight, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents, Maximum Tolerated Dose, Glucagon-Like Peptide 1, Waist Circumference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. https://app.cochat.ai/papers/10.1056/nejmoa2416394
- The paper
- Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., & Dunn, J. P. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2416394
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.